Wednesday, February 12, 2025
spot_img

Kaldalón hf.: Expansion of the KALD 041139 GB Bond Series

Kaldalón hf. has completed an expansion of its bond series KALD 041139 GB by issuing green bonds totaling ISK 1.8 billion at a yield of 3.90%. Following this expansion, the total nominal value of the series will amount to ISK 5.8 billion. 

The bond series is green and inflation-linked, featuring a 30-year repayment schedule with a fixed annual interest rate of 3.75% and semi-annual equal payments. The bonds are issued in nominal value units of ISK 20 million. This bond series is secured under the company’s general collateral arrangement and is issued under Kaldalón hf.’s ISK 30 billion bond issuance framework.

The settlement and payment date is scheduled for Friday, February 21, 2024. The proceeds from the bond issuance will be used to refinance the company’s existing debt. 

A base prospectus and an appendix to the base prospectus have been published in connection with the company’s issuance framework. The base prospectus, final terms, and other relevant documents concerning the bond issuance and the admission of the bonds to trading on the stock exchange will be made available on the company’s website: kaldalon.is/fjarfestar.

For further information, please contact:
Sigurbjörg Ólafsdóttir, CFO of Kaldalón hf.
Phone: +354 856 7155
Email: [email protected]

Powered by SlickText.com

Hot this week

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie...

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary...

P10 Reports Fourth Quarter and Full Year 2024 Earnings Results

Generated Record Quarterly Revenue of $85 Million, a 35%...

Bitdeer Announces January 2025 Production and Operations Update

- First trial batch of SEALMINER A2 air cooled...

Topics

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie...

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary...

P10 Reports Fourth Quarter and Full Year 2024 Earnings Results

Generated Record Quarterly Revenue of $85 Million, a 35%...

Bitdeer Announces January 2025 Production and Operations Update

- First trial batch of SEALMINER A2 air cooled...

Eminent Closes Acquisition of Celts Project in Nevada

VANCOUVER, British Columbia, Feb. 12, 2025 (GLOBE...

Optiva Launches Agentic AI for Telecom BSS, Powered by Google’s Gemini Models

Award-winning BSS platform now seamlessly incorporates virtual generative AI...
spot_img

Related Articles

Popular Categories

spot_img